Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel A Dammert

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Nucleic Acids Research|June 4, 2016
Heat shock represses rRNA synthesis by inactivation of TIF-IA and lncRNA-dependent changes in nucleosome positioningZhongliang Zhao, Marcel A Dammert, Sven Hoppe, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Nucleic Acids Research|November 24, 2011
ELM--the database of eukaryotic linear motifsHolger Dinkel, Sushama Michael, Robert J Weatheritt, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cell Reports|September 21, 2017
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaJohannes Brägelmann, Marcel A Dammert, Felix Dietlein, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Nucleic Acids Research|June 4, 2016
Heat shock represses rRNA synthesis by inactivation of TIF-IA and lncRNA-dependent changes in nucleosome positioningZhongliang Zhao, Marcel A Dammert, Sven Hoppe, et al.
Molecular Cancer Therapeutics|March 5, 2022
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationLisa Werr, Dennis Plenker, Marcel A Dammert, et al.
Nature Communications|April 7, 2021
Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypesChristina M Bebber, Emily S Thomas, Jenny Stroh, et al.
Nucleic Acids Research|November 24, 2011
ELM--the database of eukaryotic linear motifsHolger Dinkel, Sushama Michael, Robert J Weatheritt, et al.
Nature Communications|August 4, 2019
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancerMarcel A Dammert, Johannes Brägelmann, Rachelle R Olsen, et al.
Cell Reports|September 21, 2017
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline CarcinomaJohannes Brägelmann, Marcel A Dammert, Felix Dietlein, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Nature Communications|September 18, 2021
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IJohannes Brägelmann, Carina Lorenz, Sven Borchmann, et al.
The Journal of Clinical Investigation|February 12, 2026
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastomaLisa Werr, Jana Boland, Josephine Petersen, et al.
Pageof 1